Management of Crohn's disease has traditionally placed high value on subjective symptom assessment; however, it is increasingly appreciated that patient symptoms and objective parameters of inflammation can be disconnected. Therefore, strategies that objectively
Introduction
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) characterised by periods of symptomatic relapse and remission. Inflammation often persists in the absence of gastrointestinal (GI) symptoms 1 and may lead to progressive bowel damage and complications such as fistulae, abscesses and strictures. In many patients, impaired bowel function ultimately leads to impaired quality of life (QOL) and disability. 2 Therefore, treatment goals in CD are evolving beyond mere control of symptoms towards targeting sustained control of GI inflammation, with the ultimate objectives of preventing bowel damage, reducing long-term disability and maintaining QOL. 3, 4 As such, assessment of objective measures of inflammation is an increasingly important part of the management approach in a CD patient. Thorough assessment of disease activity and extent at presentation is needed to ensure a correct diagnosis of IBD (versus non-IBD) and of CD (versus ulcerative colitis), avoid delay in diagnosis, identify complications and help assess prognosis. This information enables appropriate treatment and increases the likelihood of achieving management goals. [5] [6] [7] During follow-up, clinical decision-making is increasingly being driven by the findings of continued monitoring (for objective evidence of inflammation), with the aim of optimising treatment for tight disease control. 8 Despite the potential benefits of longitudinal monitoring in CD, there are several unanswered questions around implementing this model in practice: Which monitoring tools should be used? When should they be used? How should the monitoring strategy differ in different patient scenarios?
Given the uncertainties around these issues, practice recommendations were developed based on the best published evidence available and/or expert opinion as part of the IBD Ahead 2011 educational programme, which involved approximately 600 gastroenterologists from 36 countries (see Appendix A). Here we provide a physician's perspective on a thorough and appropriate baseline assessment, and the 663 665 subsequent optimised monitoring in symptomatic, asymptomatic and post-operative CD patients.
Monitoring tools for CD
In CD, disease activity can be evaluated by symptom assessment, endoscopic assessment, measurement of biomarkers and cross-sectional imaging.
Symptom-based monitoring
Several scoring systems have been developed to evaluate the severity of symptoms in patients with CD (Box 1). The Crohn's Disease Activity Index (CDAI) 9 and the HarveyBradshaw Index (HBI) 10 evaluate bowel-related symptoms, complications and general well-being, while the Inflammatory Bowel Disease Questionnaire (IBDQ) 11, 12 incorporates social, systemic and emotional symptoms together with bowel-related symptoms. These indices are routinely used in clinical trials to assess drug treatments and are becoming more commonly used in clinical practice, as the threshold for reimbursement for biologic treatment in some countries is assessed using symptom-based scoring. Using indices that are responsive to changes in disease severity has value in allowing consistent longitudinal monitoring of symptoms; however, it must be noted that some items of the CDAI are open to subjective interpretation (e.g. "general well-being" or "severity of abdominal pain"). 13 Subjectivity may also impact on the ability of the IBDQ to accurately assess bowel or systemic symptoms 14 ; nevertheless, it has shown reliability and validity in assessing QOL domains in CD. 12, 15 
Endoscopy
Mucosal healing has emerged as an important goal in CD management. Several endoscopic scoring systems have been developed to facilitate consistent and reproducible assessment of the severity of mucosal damage at predefined sites (Box 1). [16] [17] [18] These instruments assess both disease extent and severity, and are now routinely used in clinical trials. However, lack of a single standardised endoscopy score and broadly accepted or validated thresholds for active disease and endoscopic remission, together with insufficient knowledge of the natural history of different lesions, have precluded their widespread use in routine clinical practice. In addition, endoscopy is invasive, costly, time-consuming and disliked by patients; therefore, it is performed only to inform critical treatment decisions.
Laboratory-based monitoring
Multiple biomarkers that reflect the presence of active inflammation have been identified; however, very few have proven to be clinically useful in IBD. C-reactive protein (CRP), an acute-phase reactant that correlates moderately well with clinical, endoscopic, histologic, and radiographic disease activity, is inexpensive to measure with a readily available blood test. [19] [20] [21] [22] [23] [24] [25] Faecal calprotectin and lactoferrin are heat-stable granulocyte-derived proteins that are relatively inexpensive, non-invasive, and have been studied extensively in IBD. [26] [27] [28] [29] [30] Both biomarkers can be assayed directly in stool using ELISA-based testing. They have been shown to correlate significantly with colonic endoscopic score and histology in Box 1. Symptom-based and endoscopic scoring systems in Crohn's disease.
Symptom-based scoring systems Crohn's Disease Activity Index (CDAI) 9 • Consists of eight factors, including frequency of soft/ liquid stools, severity of abdominal pain, general wellbeing, presence of extraintestinal manifestations, requirement for antidiarrhoeal medication, presence of an abdominal mass, haematocrit level and percentage deviation from standard body weight.
Harvey-Bradshaw Index (HBI) 10 • A simple index restricted to clinical parameters of general well-being, abdominal pain, frequency of liquid stools, presence of an abdominal mass and extraintestinal manifestations.
Inflammatory Bowel Disease Questionnaire (IBDQ) 11, 12 • Incorporates social, systemic and emotional symptoms together with bowel-related symptoms into an activity index.
• Shown to be valid and reliable across several different language and culture settings.
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• May have a stronger correlation with utility than the CDAI.
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• A shortened version of the IBDQ has also been developed and is considered able to detect meaningful clinical changes in health-related quality of life.
112
Endoscopic scoring systems
Crohn's Disease Endoscopic Index of Severity (CDEIS) 16 • Five segments are individually scored based on the presence of deep or superficial ulcerations and the extent of surface involved by disease or ulcerations. The presence of stenosis is also scored.
• Scores range from 0-44, with a higher score indicting greater severity.
Simple Endoscopic Score for Crohn's Disease (SES-CD) 17 • Five segments are individually scored based on the presence and size of ulcers, extent of the ulcerated surface, extent of the affected surface and the presence and type of narrowings.
• Scores range from 0-56, with a higher score indicting greater severity.
• SES-CD has been shown to correlate strongly with the CDEIS and also with symptom-related measures. 113 Rutgeerts score for post-operative recurrence 18 • Lesions at the neoterminal ileum and ileocolonic anastomosis are explored and scored on a scale from i0 to i4.
• Score has been shown to predict the duration of symptom-free survival. 18 patients with ileocolonic or colonic disease, although not with ileal endoscopic score and histological findings in ileal disease. 31, 32 However, there are limitations to using CRP and stool biomarkers to monitor CD activity as they are not specific for IBD. Furthermore, no validated thresholds that define active disease and biochemical remission exist.
Cross-sectional imaging
Cross-sectional imaging tools are important in CD for establishing disease severity and extent, as well as ruling out complications. As such, they can aid diagnosis and guide therapeutic strategies. Cross-sectional imaging may complement endoscopic assessment by providing additional insight into disease activity, allowing assessment of the entire small bowel and excluding complications such as stenosis or penetrating disease. Various cross-sectional imaging tools are available (Table 1) , including magnetic resonance imaging (MRI), ultrasonography and computed tomography (CT). MRI is considered one of the reference standards in the diagnostic assessment of CD. 33 It allows high soft-tissue contrast and has static, dynamic and direct multiplanar imaging capabilities. MRI accuracy is optimised with the use of luminal and intravenous contrast and can be used to evaluate the activity of small-and large-bowel disease and to document complications including stenosis, fistula and abscess. Pelvic MRI is the modality of choice for imaging the pelvis and perianal area. Ultrasonography is a relatively accessible tool for an urgent broad assessment of disease activity and for exclusion of complications, with high reproducibility and low inter-observer variability. 33, 34 It is minimally invasive and an ionising radiation-free tool. Contrast-enhanced ultrasonography allows microvascular imaging of the bowel and quantitative differentiation between inflamed and normal bowel segments based on their different diffusion pattern 35 ; however, it does not allow differentiation between predominantly inflammatory or fibrotic stenosis. 36 CT enterography combines CT techniques with oral and intravenous contrast. 37 It has similar advantages to MR enterography; however, ionising radiation exposure limits its use to emergency situations. Table 2 provides a summary of the final statements from the IBD Ahead 2011 programme. These statements, together with the level of supporting evidence, are provided in Appendix A.
Monitoring in different patient scenarios

At diagnosis
Careful evaluation of disease characteristics at baseline is essential for differential diagnosis, establishing the extent, severity and behaviour of disease, objectively evaluating inflammation and ruling out complications. Initial findings inform both prognostic assessment and treatment decisions and also provide a baseline for future follow-up. For these reasons, care should be taken to use standardised tools accurately. It is imperative that a complete assessment be made at diagnosis and, where resources allow, we propose that all four assessment modalities -symptom assessment, endoscopic assessment, laboratory markers and cross-sectional imaging -are used. This will serve as a baseline from which disease evolution and management success can be evaluated.
In clinical practice, gastroenterologists typically rely on their global clinical judgement for symptom evaluation; however, use of a standardised tool (see Box 1) that is responsive to changes in disease severity from diagnosis onwards might allow greater objective and valid assessment. We encourage use of the HBI as it is simple to administer, amenable to same-day clinic visits, relatively well correlated to CDAI scores, 10, 38 and has a higher objective component than the IBDQ.
Endoscopy should be performed in all patients with symptoms suggestive of IBD to enable diagnosis and assess the location, extent and severity of mucosal lesions. We strongly suggest using precise and standardised descriptions of endoscopic lesions, including type, location, depth and extent. Scoring of severity may be achieved with the Crohn's Disease Endoscopic Index of Severity (CDEIS) 16 or Simple Endoscopic Score for Crohn's Disease (SES-CD), 17 although use of these tools may not be practical in routine clinical practice. Ileocolonoscopy examining the terminal ileum and all colonic segments, with precise description of lesions, biopsy and subsequent histological examination, is needed to support the diagnosis, as well as to differentiate IBD from other causes of colitis, and CD from ulcerative colitis. [39] [40] [41] Biopsies should be taken from endoscopically affected and non-affected areas to histologically document the existence of spare segments between areas of inflammation. When biopsy of abnormal areas is not within the reach of the standard gastroscope or ileocolonoscope, then single-or doubleballoon enteroscopy should be considered. 22, 23 Upper GI endoscopy/biopsy may be useful, particularly in paediatric patients and in adult patients with upper GI symptoms. In a patient in whom there is high clinical suspicion of CD but inconclusive ileocolonoscopy, gastroscopy, cross-sectional imaging and small-bowel capsule endoscopy (SBCE) may aid diagnosis and should be considered. 42 In our opinion routine blood tests, (complete blood count, liver profile, albumin, iron studies, renal function, vitamin B12 and assessment of CRP and stool biomarkers) should be conducted in all patients to establish baseline values for future comparison. Initial assessment of CRP has an important diagnostic and prognostic role 19, 23, [43] [44] [45] ; however, it should be noted that approximately 20% of patients with active CD may have normal CRP levels. 46 While the sensitivity and specificity of the CRP test are not high enough to allow differentiation from other disorders, thus precluding its use as an IBD screening tool, 47 faecal calprotectin and faecal lactoferrin can help differentiate suspected IBD from IBS or functional disease. 24, 28, 30, 31, [48] [49] [50] A meta-analysis of 13 studies found that faecal calprotectin had a pooled sensitivity of 93% and pooled specificity of 96% to diagnose IBD in adults; corresponding sensitivity and specificity in children and teenagers were 92% and 76%, respectively. 28 A larger review, including 30 studies, found that faecal calprotectin had a sensitivity of 95% and specificity of 91% for differentiating IBD from non-IBD diagnoses. 30 In addition, the diagnostic precision of faecal calprotectin was greater with a cut-off of 100 μg/g compared with 50 μg/g. We propose that cross-sectional imaging is needed in all patients at diagnosis to assess the extent and severity of small bowel involvement and to rule out complications such as stenosing or penetrating disease, which may not be detected by symptom assessment or endoscopy alone. A systematic review of published studies calculated the specificity and sensitivity of MRI in the diagnosis of CD to be 78% and 85%, respectively; corresponding values for ultrasonography were 85% and 98%, respectively (Table 1) . 51 The accuracy of CT for CD diagnosis has not been robustly evaluated in prospective studies. 51 A number of findings at MRI have been validated for the diagnosis of active and severe CD, and quantitative indices of activity have been developed to facilitate objective interpretation of MR images. 52, 53 MR enterography is our preferred modality for baseline assessment. It is accurate for establishing disease extent and severity, 51, 52, 54 has been shown to be as effective as endoscopy for diagnosis of CD in some studies, 55, 56 and is superior to conventional enteroclysis and small-bowel follow-through (SBFT). 57 Dedicated small-bowel ultrasonography, a standard diagnostic tool in many countries, may also be useful where expertise exists. 33 Small-bowel contrast-enhanced ultrasonography is superior to plain abdominal ultrasound and SBFT in detecting and documenting the extent of small-bowel lesions in CD. 58 Contrast-enhanced pelvic MRI and/or rectal or transperineal ultrasonography are advocated, in combination with examination under anaesthesia, to evaluate the anatomy, extent and severity of perianal disease and detect perianal abscesses needing urgent treatment. 59 MRI can also evaluate fistula anatomy and differentiate between simple and complex fistulas, as well as determine therapeutic effect in fistulising CD patients. 60 Anorectal ultrasound can also detect lesions of the internal and external anal sphincters, evaluate the presence of interspincteric abscess and guide transcutaneous drainage 61 ; however, because of the discomfort associated with this procedure, pelvic MRI is favoured where possible.
Symptomatic patients
Routine monitoring of symptomatic patients is important to optimise therapy and ensure adequate response. We advise that symptoms are assessed at each visit, the frequency of which will depend on disease severity, treatment and response. Again, the consistent use of a standardised tool [9] [10] [11] [12] will likely help assessment of response to treatment. We advocate that symptoms be re-evaluated 2-4 weeks after initiating steroids, 3-6 months after initiating immunosuppressive therapy 62 and 8-12 weeks after initiating biological therapy. 63 More frequent visits are recommended in patients with moderate-to-severe disease to rule out deterioration of the clinical condition. If a patient has symptoms that persist despite treatment, further investigations should be performed to rule out complications and reassess disease severity.
Objective evidence of inflammation is of utmost importance in patients being considered for biological therapy. In a post-hoc exploratory analysis of the SONIC study, which compared infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderateto-severe CD who had not undergone previous immunosuppressive or biologic therapy, the effects of infliximab were significantly more pronounced in patients with elevated baseline CRP levels, baseline mucosal lesions, and both elevated baseline CRP levels and mucosal lesions. 64 This underscores the importance of endoscopic exploration or evaluation of inflammatory biomarkers prior to starting treatment. SBCE or enteroscopy may be considered to look for mucosal lesions in patients with negative ileocolonoscopy and imaging evaluations when objectively establishing the presence of disease activity before the initiation of biological therapy.
While mucosal healing has been associated with improved clinical outcomes in CD, 3, [65] [66] [67] [68] there is a paucity of evidence to guide endoscopic monitoring in symptomatic patients during treatment. A poor correlation exists between endoscopic inflammation and symptom scores after steroid treatment 69 ; however, this correlation may be better with biologic treatment. 70 We suggest that endoscopy should be performed to evaluate therapeutic response in patients with persistent or recurrent symptoms despite therapy or more globally when there is a doubt about disease control and concern about disease progression. The extent of endoscopic re-evaluation should be determined based upon known sites of involvement and clinical presentation. Our recommendation is that performance of a limited number of laboratory investigations has value in the monitoring of symptomatic patients to assess disease activity and exclude intercurrent infection. Prospective studies have established the value of CRP as a marker of the presence and severity of inflammatory activity, 1, 19, 20, 22, 45, [71] [72] [73] [74] although it should be noted that CRP may be normal in patients with active CD. 46 Furthermore, CRP may have a role in evaluating response to therapy. For example, in CD patients treated with anti-tumour necrosis factor (TNF) therapy, an elevated baseline CRP has been shown to correlate with response 75, 76 and early normalisation of CRP levels predicts sustained long-term response and mucosal healing. 77 Faecal calprotectin and, to a lesser degree, lactoferrin can be used to differentiate between clinically active and inactive IBD, as well as estimate the degree of mucosal inflammation, as they correlate better with endoscopic inflammation than CRP or white blood cell count. 20, 25, 32, [78] [79] [80] [81] Faecal markers may also have a role in the monitoring of therapeutic response: in clinical trials of CD therapies, "normalisation" of faecal markers appeared to be a useful and reliable surrogate for mucosal improvement and healing. 78, 79 However, as with CRP, it should be noted that faecal calprotectin and lactoferrin may be normal in patients with clinically and endoscopically active CD, particularly ileal disease. 32 We advise that inflammatory markers should be assessed to confirm active disease before starting or switching therapy, 64 with reassessment at intervals determined by disease severity, treatment type and therapeutic response.
Symptomatic patients with small-bowel disease should have small-bowel cross-sectional imaging prior to starting therapy (and during therapy if they remain symptomatic) to assess the activity of the disease and exclude complications. Currently, the frequency of repeat imaging will depend on the clinical circumstances. The optimum frequency of assessment is unknown. For assessment of complications, plain radiographs are useful in patients with severe or fulminant symptoms for detection of bowel obstruction, perforation or toxic megacolon. 82 Routine use of CT enterography should be avoided because of the radiation risk. However, contrast-enhanced CT of the abdomen/pelvis or ultrasonography is useful and necessary in acutely ill patients to rule out complications, such as intra-abdominal abscess.
83,84 MR enterography should be used to assess the extent and severity of small-bowel disease. MRI parameters have been found to correlate with acute inflammatory score. 85 Small-bowel ultrasonography may also be useful, particularly in patients with disease located in the terminal ileum. 51 
Asymptomatic patients
In asymptomatic patients, monitoring is needed to ensure sustained control of inflammation beyond symptoms. Patients in remission will typically visit the clinic every 3-6 months, although patients with very indolent and stable disease may only need to be seen every 12 months.
Symptom assessment forms part of a global approach to assess remission at each visit. 86 At the very least, the HBI or another standardised symptom assessment tool should be used to allow assessments to be longitudinally evaluated using quantitative criteria. [9] [10] [11] [12] Endoscopy is invasive and is not typically used to assess asymptomatic patients, other than when therapy cessation is being considered after a long-term remission or when there is discrepancy between symptoms and objective measures of inflammation (e.g. elevated CRP or faecal calprotectin). Endoscopic remission (CDEIS = 0) was independently associated with a more than two-fold reduction in risk of relapse in a prospective study of infliximab withdrawal in 115 patients with CD who had been treated for at least 1 year with infliximab and an antimetabolite and had been in corticosteroid-free remission for at least 6 months (hazard ratio 2.3; 95% CI 1.1-4.9; p = 0.04). 87 Endoscopy (ileocolonoscopy in ileocolonic disease and upper-GI endoscopy in patients with upper-GI involvement) ought to be considered in asymptomatic patients when there is concern about disease progression and when therapeutic modifications are considered. Precise standardised description of endoscopic lesions including type, location, depth and extent is advocated.
We suggest that laboratory investigations form a routine part of the global assessment at each visit in asymptomatic patients. Complete blood count, liver profile and renal function should be conducted every 3-12 months to monitor treatment side effects. Monitoring CRP and faecal calprotectin is a useful trigger for re-exploration by endoscopy and/or cross-sectional imaging. CRP may be useful in predicting short-term prognosis and relapse. 21, 88, 89 The prognostic value of stool markers to predict relapse is of major interest in view of their correlation with endoscopic activity in CD, 25, 32 and there is evidence to support the use of calprotectin and, to a lesser degree, lactoferrin in this setting. In studies evaluating a single faecal sample, calprotectin was a reliable predictor of relapse in IBD with colonic involvement over a 1-year follow-up period. 26, [90] [91] [92] [93] [94] [95] [96] However the optimal cut-off threshold has not yet been established and may depend on the clinical situation and the desire to favour high sensitivity over high specificity or vice versa. A continuous comparison between serial CRP values should be performed in individual patients, with any increase above previous values prompting further investigation for possible relapse.
There are very few data evaluating cross-sectional imaging in the asymptomatic CD patient. Our opinion is that cross-sectional imaging may be appropriate in high-risk patients when concern exists about disease progression, there is a discrepancy between symptoms and inflammatory biomarkers and when therapeutic modifications are being considered. In this setting we advocate MR enterography or abdominal ultrasonography, and the avoidance of repeat exposure to ionising radiation.
Post-operative patients
Recurrence following a resection for CD is common, 18 with a rate of endoscopic recurrence at the anastomosis of 65-90% within 1 year of surgery. [97] [98] [99] Monitoring is needed to detect early recurrence and to identify complications. Although the CDAI has been shown to have some value in identifying post-operative recurrence of CD, 100 there are few data to guide symptom assessment in post-operative patients. CD symptoms should be assessed within 3 months of surgery, preferably using the CDAI or HBI. Symptoms should continue to be monitored regularly (e.g. every 3 months) in the first year following surgery, then every 6-12 months thereafter, depending on the risk of recurrence. It is important to note that symptoms may be functionally derived, particularly in the post-operative setting, highlighting the importance of comprehensive monitoring of post-operative patients.
Disease often first recurs in the absence of symptoms, 97 ,100,101 and symptoms associated with surgery, particularly diarrhoea, may be misinterpreted as a manifestation of disease recurrence. Therefore, the assessment of objective parameters of inflammation is also required to monitor for postoperative recurrence. Endoscopic recurrence precedes clinical recurrence and severe endoscopic appearance predicts a poor prognosis. 18 Ileocolonoscopy should therefore be the gold-standard monitoring tool in this setting to detect and define the presence and severity of morphological recurrence. We consider that capsule endoscopy is a potential alternative in selected patients who have had mid-small bowel resections that are not evaluable by ileocolonoscopy. 42, 102, 103 The Rutgeerts score was developed for lesions in the neoterminal ileum and at the ileocolonic anastomosis and correlates with future clinical behaviour 18 ; we advocate its use for the assessment of recurrence in the neoterminal ileum. Endoscopy should be performed at 6-12 months following surgery, with the frequency of further endoscopies depending on the findings of the first evaluation and on the future disease course.
Very few studies have evaluated the use of biomarkers in the post-operative setting, and there is no good correlation between CRP (or erythrocyte sedimentation rate) and endoscopy score for recurrence at 1 year. 101 We propose routine laboratory investigations during follow up after ileal or colonic resections, including assessment of vitamin B12 levels, and CRP assessment every 3-6 months. Faecal calprotectin and lactoferrin may have a role in predicting early recurrence [104] [105] [106] ; therefore, we propose that faecal calprotectin is evaluated 3 months post surgery, with consideration of an earlier endoscopy if an increase is seen, and then after the first endoscopy as in the follow-up of asymptomatic patients.
Cross-sectional imaging may be used where disease activity or structural complications are suspected, and where endoscopy is inconclusive. MR enterography, 107 CT enterography 108 and contrast-enhanced ultrasonography 109 may be used, with the frequency of imaging varying on a case-by-case basis, although data are limited.
Future directions
The opinions in this article are largely based on clinical experience, given the current lack of integrated evidence to guide optimal monitoring in CD, particularly with respect to the most appropriate time points for using the available tools in different patient scenarios. There is a need for simple, reproducible scoring systems and reading methodologies for endoscopy, and for further training in this area. Refinement and validation of endoscopic cut-offs is another important area for future research; currently, the level of tolerable mucosal ulceration and the thresholds at which treatment should be intensified for optimal clinical outcomes are unknown. Further validation of non-endoscopic markers of disease activity and treatment response is also awaited, as is the development and validation of new biomarkers and other surrogates of endoscopy. In addition, we need to standardise documentation for patients with CD to allow ease of transfer between healthcare teams and sites.
Available instruments measure disease activity at a fixed point in time. The Lémann score, currently the subject of a cross-sectional validation study, will enable the assessment of cumulative structural damage to the bowel as measured by appropriate imaging modalities and medical history. It has potential for use initially within clinical studies to assess the effect of therapies on the progression of bowel damage.
A number of ongoing clinical studies will provide further data and assess the impact on clinical outcomes of a 'tight control' approach to treatment, based around objective parameters of inflammation. Long-term studies are needed to define and validate the optimal treatment targets in CD. There is much interest currently in the concept of 'deep remission' (defined in the EXTEND study as combined mucosal healing and symptomatic remission 4 ) as a potential treatment goal.
Conclusions
The IBD Ahead 2011 programme has informed practice guidance for the monitoring of patients with CD to facilitate the achievement of tight disease control through sustained control of inflammation in this progressive condition. Key points include the need to measure and record baseline parameters to enable subsequent tracking of disease activity and progression of lesions; to adopt different approaches in different patient scenarios; to regularly monitor disease activity using objective markers of inflammation, rather than relying on symptomatic assessment; to measure and document precise and standardised descriptions of endoscopic lesions including type, location, depth and extent; and to use cross-sectional imaging for complete assessment of lesions where necessary, and for assessment of stenosing and penetrating complications. We hope that this provides helpful guidance to gastroenterologists in the monitoring of CD within daily clinical practice.
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